OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Gut microbiome, prebiotics, intestinal permeability and diabetes complications	79
Menopausal hormone therapy for the management of osteoporosis	74
Gut microbiome and bile acids in obesity-related diseases	70
Basics of androgen synthesis and action	61
Epidemiology and mortality of Cushing’s syndrome	61
Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression	52
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency	50
Genetics of ovarian insufficiency and defects of folliculogenesis	48
Genetic underpinnings of asthenozoospermia	46
Gut microbiome and thyroid autoimmunity	42
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	40
Genetics of teratozoospermia: Back to the head	39
Phthalates, ovarian function and fertility in adulthood	35
Endocrine-disrupting chemicals and their effects on puberty	35
Acquisition of peak bone mass	35
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	32
Genetic mutations contributing to non-obstructive azoospermia	31
Immune checkpoint inhibitor-related thyroid dysfunction	30
Genetics and epigenetics of autoimmune thyroid diseases: Translational implications	30
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism	29
Menopausal hormone therapy and breast cancer risk	29
Endocrine disruptors and the male reproductive system	28
Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide	27
Endocrine disrupting chemicals and bone	27
Thyroid hormone system disrupting chemicals	27

Cardiovascular complications of mild autonomous cortisol secretion	25
Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing’s syndrome	25
Genetics of 46,XY gonadal dysgenesis	25
Endocrine-disrupting chemicals and child health	24
Genetics of cryptorchidism and testicular regression	23
Diagnosis and management of premature ovarian insufficiency	22
Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease	22
Androgens and male sexual function	22
The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders	22
Anaplastic thyroid cancer: An update	21
Gut microbiota and metabolic aspects of cancer cachexia	21
Cognitive health after menopause: Does menopausal hormone therapy affect it?	20
Haematological actions of androgens	19
Quality of life in Cushing’s syndrome	19
Marrow adipogenic lineage precursor: A new cellular component of marrow adipose tissue	19
Statins and diabetes: What are the connections?	19
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	19
Regulation of bone mass in inflammatory diseases	19
Prenatal exposure to phthalate esters and its impact on child development	19
Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases	18
Steroid profiling in the diagnosis of mild and overt Cushing’s syndrome	18
Differentiated thyroid carcinoma: An update	18
Paraneoplastic autoimmune hypophysitis: An emerging concept	17
Biochemical diagnosis of Cushing’s disease: Screening and confirmatory testing	17
New types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome	17
Pathophysiology of thyroid-associated orbitopathy	17
Genetics of anti-Müllerian hormone and its signaling pathway	17
Chemokines in thyroid autoimmunity	16
Immune checkpoint inhibitor-related hypophysitis	16
Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy	16
Menopausal hormone therapy in women with medical conditions	15
Hypercoagulability in Cushing’s syndrome: From arterial to venous disease	15
COVID-19 vaccination and thyroiditis	15
The bidirectional interaction of COVID-19 infections and lipoproteins	15
Hormone therapy and cardiovascular disease: Benefits and harms	15
Gut microbiota and their metabolites in cardiovascular disease	15
Infertility considerations in klinefelter syndrome: From origin to management	15
Auto-immunity and the gut microbiome in type 1 diabetes: Lessons from rodent and human studies	15
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	15
Neural regulation of bone marrow adipose tissue	14
Active surveillance of low-risk papillary thyroid microcarcinoma	14
The definition of remission and recurrence of Cushing’s disease	14
Primary hyperparathyroidism	13
Effects of endocrine disorders on lipids and lipoproteins	13
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	13
Endocrine-disrupting chemicals and behaviour: A high risk to take?	13
COVID-induced thyroid autoimmunity	13
Temozolomide in aggressive pituitary tumours and pituitary carcinomas	13
Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses	13
Angiopoietin-like 3: An important protein in regulating lipoprotein levels	12

Pediatric thyroid cancer: Recent developments	12
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	12
Congenital disorders of estrogen biosynthesis and action	12
In utero exposure to phthalates and reproductive toxicity in rodents	12
Omega-3-fatty acids: Do they prevent cardiovascular disease?	12
Type 1 diabetes related to immune checkpoint inhibitors	12
Epigenetic regulation of bone mass	12
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	12
Medullary thyroid cancer - An update	12
SARS-CoV-2 infection and its effects on the endocrine system	11
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	11
Genetics of pubertal timing	11
Molecular testing in thyroid cancer diagnosis and management	11
Pituitary and SARS CoV-2: An unremitting conundrum	11
Clinical imaging of marrow adiposity	11
The role of hormone therapy in urogenital health after menopause	10
Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity	10
Associations of prenatal exposure to phthalates and one phthalate substitute with anthropometric measures in early life: Results from the German LIFE Child cohort study	10
Clinical implications of Y chromosome microdeletions among infertile men	10
COVID-19 and metabolic syndrome	10
Exercise and physical activity in individuals at risk of fracture	10
Updates in the outcomes of radiation therapy for Cushing’s disease	10
Remnant lipoprotein particles and cardiovascular disease risk	10
Genetics of congenital central hypogonadism	10
Endocrine abnormality in paraneoplastic syndrome	9
Kallman syndrome and central non-obstructive azoospermia	9
Bone marrow adipocytes – Good, bad, or just different?	9
The effect of osteoporosis treatment on bone mass	9
Medical therapy in severe hypercortisolism	9
Sperm genetic abnormalities and their contribution to embryo aneuploidy & miscarriage	9
Androgens, sports, and detection strategies for anabolic drug use	8
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	8
Long-term thionamide antithyroid treatment of Graves' disease	8
Genomic and epigenomic profile of thyroid cancer	8
Common symptoms associated with usage and cessation of anabolic androgenic steroids in men	8
Faecal microbiota transplantation in endocrine diseases and obesity	8
Innovative therapeutics in acromegaly	8
Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?	7
Thyroid autoimmunity and pregnancy in euthyroid women	7
Radioiodine therapy in the different stages of differentiated thyroid cancer	7
Menopause: Physiology, definitions, and symptoms	7
Epigenetic mechanisms within the sperm epigenome and their diagnostic potential	6
Effects of androgens on glucose metabolism	6
Cardiovascular health and the menopause, metabolic health	6
Management of patients with statin intolerance	6
MicroRNAs in autoimmune thyroid diseases and their role as biomarkers	6
New advances in menopause symptom management	6
Menopausal hormone therapy in women with benign gynaecological conditions and cancer	6
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	6
SARS-CoV-2 infection and female reproductive health: A narrative review	6
Therapeutic effects of androgens for cachexia	6
The role of androgens in transgender medicine	6
Endocrine-disrupting chemicals	5
Quality of life in thyroid cancer	5
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	5
Premature ovarian insufficiency, early menopause, and induced menopause	5
History of androgens and androgen action	5
The role of reoperation after recurrence of Cushing’s disease	5
Nonalcoholic fatty liver disease and adult growth hormone deficiency: An under-recognized association?	5
Androgen-based therapies in women	5
Surgical treatment of thyroid cancer: Established and novel approaches	5
Novel androgen therapies including selective androgen receptor modulators	5
Genotype-phenotype correlations in Graves’ disease	5
Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks	4
Growth hormone deficiency in adults with Cushing's disease	4
Recurrence risk of autoimmune thyroid and endocrine diseases	4
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	4
The pathophysiology of hypophosphatemia	4
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	4
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	4
Approach to patients with elevated low-density lipoprotein cholesterol levels	4
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	4
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	4
Myeloma and marrow adiposity: Unanswered questions and future directions	4
Congenital absence of the vas deferens: Cystic fibrosis transmembrane regulatory gene mutations	4
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	4
Bone health and menopause: Osteoporosis prevention and treatment	4
Ageing male (part 2): Management of functional hypogonadism in older men, a patient-centric holistic approach	4
Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates?	4